



## Aspartate transaminase to platelet ratio index (APRI) to assess liver fibrosis in patients with chronic liver disease

Caterina Anania<sup>1</sup>, Lucia Pacifico<sup>1\*</sup>, Flavia Ferraro<sup>1</sup>, Eugenia Olivero<sup>1</sup>, Claudio Chiesa<sup>2</sup>

<sup>1</sup> Department of Paediatrics and Child Neuropsychiatry, Sapienza University of Rome, Rome, Italy

<sup>2</sup> Institute of Translational Pharmacology, National Council Research, Rome, Italy

### ARTICLE INFO

*Article Type:*  
Letter to Editor

*Article history:*  
Received: 01 Apr 2011  
Revised: 06 Apr 2011  
Accepted: 09 Apr 2011

*Keywords:*  
Liver fibrosis  
Liver disease  
Aspartate transaminase

► *Please cite this paper as:*

Anania C, Pacifico L, Ferraro F, Olivero E, Chiesa C. Aspartate transaminase to platelet ratio index (APRI) to assess liver fibrosis in patients with chronic liver disease. *Hepat Mon.* 2011;11(6):479-80.

© 2011 Kowsar M.P.Co. All rights reserved.

### Dear Editor,

In patients with chronic liver disease (CLD), liver biopsy is currently an indispensable reference method to assess inflammatory activity and fibrosis stage and thus to estimate prognosis and guide management decisions in such patients. Given that the presence of advanced fibrosis is a predictor of nonresponse, the decision (1) to begin antiviral therapy in cases of chronic viral hepatitis is highly influenced by the stage of liver fibrosis. For example, in chronic hepatitis C (CHC) patients, the stage of liver fibrosis is a predictor of response to interferon-based treatment. Despite these premises, liver biopsy has several disadvantages, including poor patient compliance, sampling error, limited usefulness for follow up, and poor intra- and interobservation agreements (2). Considering these limitations, in the last decade clinical investigators have been searching for noninvasive methods to obtain accurate information about the fibrosis stage in patients with CLD. Accordingly, a noninvasive di-

agnostic test for liver fibrosis should be simple, available to wide audiences at limited expense, able to accurately identify disease stage, and sensitive enough to track changes in fibrosis induced by the natural course of disease progression or by therapy (3). Serum biochemical tests, including direct and indirect markers of liver fibrosis, have been the subject of an intensive investigation, but their diagnostic accuracy has been reported to vary widely (3, 4). In this area, of great contemporary interest is the article by Yilmaz *et al.* on the usefulness of the aspartate transaminase to platelet ratio index (APRI) to assess liver fibrosis in patients with CLD (5). APRI is a simple and cheap method to ascertain the ratio between AST and platelets and is easy to use in clinical practice. In patients with CHC, APRI performance has been reported to vary widely in diagnostic accuracy (sensitivities between 41% and 91% and specificities between 47% and 95%) for identifying significant fibrosis. A recent systematic review (6) showed that for significant fibrosis, an APRI threshold of 0.5 was 81% sensitive and 50% specific. Furthermore, Cheung *et al.* found that in patients with CHC, APRI was better in predicting advanced versus significant fibrosis, and the authors suggested that APRI with a cutoff of 0.5 and 1.5 can be used in routine clinical practice to exclude or identify the presence of advanced fibrosis (7).

\* Corresponding author at: Lucia Pacifico, Department of Paediatrics, Sapienza University of Rome, Viale Regina Elena, P.O. Box: 324 00161, Rome, Italy. Tel: +39-0649979215, Fax: +39-0649979216.

E-mail: [lucia.pacifico@uniroma1.it](mailto:lucia.pacifico@uniroma1.it)

Consistent with the previous research, the retrospective study by Yilmaz *et al.* (5) showed that APRI has an acceptable accuracy for the assessment of liver fibrosis in patients with CHC but not in those with chronic hepatitis B (CHB). Indeed, in Yilmaz *et al.*'s study APRI was significantly associated with fibrosis scores in subjects with CHC ( $p = 0.0059$ ) but not in those with CHB ( $p = 0.1495$ ). The major finding of their study was that the APRI also had an acceptable accuracy for the assessment of liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), tending to increase with the degree of fibrosis. In previous observational studies that included patients with NAFLD, the APRI score seldom reached the value of 1 but tended to be higher in patients with advanced stages of fibrosis (8). In the early stages of NAFLD, patients usually present mild to moderate increases in aminotransferase levels, while platelet counts are usually normal. Fibrosis progresses over time, but it may remain stable for some years. Thus, the focus of the study by Yilmaz *et al.* (5) is that the APRI may be a useful asset in clinical practice to identify the natural course of NAFLD as it approaches the advanced stages. Nonetheless, much more information is needed on the potential uses of this index in the field of hepatology. More advanced stages of NAFLD appear to be associated with older age, higher BMI, diabetes, hypertension, high triglycerides, and insulin resistance (9). The findings from different studies are not completely consistent as to which factors (including APRI score) are independently associated with fibrosis progression, and

this may depend on the population studied.

## References

1. Friedman SL. Liver fibrosis – from bench to bedside. *J Hepatol.* 2003;**38** (Suppl 1):S38-53.
2. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol.* 2002;**97**(10):2614-8.
3. Sebastiani G. Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. *World J Gastroenterol.* 2009;**15**(18):2190-203.
4. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. *World J Gastroenterol.* 2006;**12**(23):3682-94.
5. Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease. *Hepat Mon.* 2011;**11**(2):103-7.
6. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. *Hepatology.* 2007;**46**(3):912-21.
7. Cheung RC, Currie S, Shen H, Bini EJ, Ho SB, Anand BS, et al. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice? *J Clin Gastroenterol.* 2008;**42**(7):827-34.
8. Loeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-Vorackova F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. *Ann Hepatol.* 2008;**7**(4):350-7.
9. Pacifico L, Poggiogalle E, Cantisani V, Menichini G, Ricci P, Ferraro F, et al. Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge. *World J Hepatol.* 2010;**2**(7):275-88.